FDA discontinue rare pediatric disease designation program despite increase in RPD approvals
Due to concerns over its effectiveness, the US Congress did not renew the RPDD program and began to close it in late 2024
Author
Akums launches high-strength Paracetamol Oral Suspension 500mg/5ml
This novel oral suspension is an addition to the analgesic and antipyretic category by offering therapeutic adult dosing in a…
FOPE & PharmaState Academy hosts session 15 PULSE Program
This session highlighted industry best practices in change control & deviations under Revised Schedule M
Session 14 of FOPE & PharmaState Academy’s PULSE Program explores investigations & CAPA…
The session attracted over 250 attendees, reinforcing the PULSE series' role as a key learning platform for industry professionals
Cipla invests in iCaltech Innovations to strengthen respiratory play
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core…
FOPE, PharmaState Academy, complete one year of the PULSE program
Session 23 focused on Manufacturing under Loan License or Contract in light of the Revised Schedule M Guidelines
Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their…
Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to…
FDA approves 127 innovator and biosimilar drugs in 2024, marks shift in pharma approval landscape
According to GlobalData, the 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting…
Venus Remedies secures WHO GDP endorsement for pharma logistics
Extending its reach directly to pharmacies and small retailers, Venus Remedies now operates a parallel online delivery system
Miltenyi Biotec and THSTI launch India’s first hands-on clinical cell manufacturing training…
The initiative aims to strengthen India’s cell and gene therapy capabilities through skill development and translational research…